[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant
Phase 1
48
about 8.2 years
18–100
6 sites in CA, KS, PA +2
About this study
This trial is testing the recommended dose of [177Lu]Lu-NeoB when used with ribociclib and fulvestrant for people with advanced breast cancer that has returned after treatment or progressed while being treated. The goal is to determine how much [177Lu]Lu-NeoB is safe and effective in this setting.
Based on ClinicalTrials.gov records.
What participants do
- 1.Goserelin
- 2.Take Fulvestrant
- 3.Take Ribociclib
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
fulvestrant, goserelin, ribociclib
injection, oral (Oral Tablet)
Primary: Incidence and nature of DLTs during the DLT observation period, Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Secondary: Clinical Benefit Rate (CBR), Duration of Response (DoR), Incidence and severity of AEs following [68Ga]Ga-NeoB administration, Objective Response Rate (ORR), Observed maximum blood concentration (Cmax) of [177Lu]Lu-NeoB, Overall Survival (OS), Progression Free Survival (PFS), Terminal elimination half-life (T^1/2) of [177Lu]Lu-NeoB
Oncology